Appendix Table 1.
Patient Characteristics | β | (SE) | p | OR | 95% CI |
---|---|---|---|---|---|
Gender (ref = Male) | |||||
Female | −0.100 | 0.078 | 0.202 | 0.905 | (0.776–1.055) |
Race (ref = Caucasian) | |||||
African American | −0.198 | 0.193 | 0.304 | 0.820 | (0.562–1.197) |
Other/Unknown | 0.309 | 0.226 | 0.172 | 1.362 | (0.874–2.122) |
Age (ref = 65–69) | |||||
70–74 | −0.613 *** | 0.155 | <.001 | 0.542 | (0.400–0.734) |
75–79 | −1.011 *** | 0.151 | <.001 | 0.364 | (0.271–0.490) |
80–84 | −2.002 *** | 0.157 | <.001 | 0.135 | (0.099–0.184) |
85+ | −3.064 *** | 0.166 | <.001 | 0.047 | (0.034–0.065) |
Education1 (ref=Quartile 1) | |||||
Quartile 2: low–med education | −0.009 | 0.112 | 0.935 | 0.991 | (0.795–1.235) |
Quartile 3: med–high education | −0.057 | 0.107 | 0.595 | 0.945 | (0.767–1.165) |
Quartile 4: highest education | 0.066 | 0.116 | 0.572 | 1.068 | (0.850–1.341) |
Primary site of tumor (ref=Cecum, | |||||
Flexures, Transverse/Descending | −0.158 * | 0.092 | 0.087 | 0.854 | (0.713–1.023) |
Large intestine/NOS | 0.291 | 0.271 | 0.283 | 1.337 | (0.787–2.273) |
Sigmoid | −0.064 | 0.093 | 0.490 | 0.938 | (0.782–1.125) |
Tumor grade (ref=poorly differentiated) | |||||
Well-differentiated | 0.005 | 0.214 | 0.980 | 1.005 | (0.660–1.530) |
Moderately differentiated | −0.070 | 0.089 | 0.429 | 0.932 | (0.783–1.109) |
Unknown | −0.461 ** | 0.198 | 0.020 | 0.631 | (0.428–0.931) |
Year of Diagnosis (ref=2003) | |||||
2004 | −0.169 * | 0.090 | 0.058 | 0.844 | (0.708–1.006) |
2005 | −0.160 * | 0.094 | 0.088 | 0.853 | (0.710–1.024) |
Dual eligibility (ref=no) | |||||
Yes | −0.726 *** | 0.105 | <.001 | 0.484 | (0.394–0.594) |
Comorbidity conditions (ref=no, for | |||||
Liver disease | 0.328 | 0.563 | 0.560 | 1.388 | (0.460–4.184) |
Rheumatoid disease or AIDs | 0.461 | 0.329 | 0.161 | 1.585 | (0.832–3.019) |
Renal disease | −0.098 | 0.366 | 0.788 | 0.906 | (0.442–1.857) |
Dementia or paralysis | −0.410 | 0.289 | 0.156 | 0.664 | (0.376–1.170) |
CHF or acute MI or CVD or COPD | −0.563 *** | 0.089 | <.001 | 0.570 | (0.479–0.678) |
Neuropathy | −0.159 | 0.262 | 0.546 | 0.854 | (0.511–1.427) |
Diabetes | −0.148 | 0.101 | 0.144 | 0.863 | (0.708–1.052) |
| |||||
Organization characteristics (of treating hospital) | |||||
| |||||
Proportion of claims from CCOP-affiliated MD or Hospital | 2.550 *** | 0.285 | <.001 | 12.806 | (7.319–22.406) |
Any Direct Cooperative group affiliation (ref=no) | −0.184 * | 0.099 | 0.064 | 0.832 | (0.685–1.011) |
Any Medical School Affiliation (ref=unaffiliated) | 0.011 | 0.116 | 0.928 | 1.011 | (0.805–1.268) |
NCI-center affiliated (ref=no) | 0.021 | 0.798 | 0.979 | 1.021 | (0.214–4.875) |
| |||||
Intercept | 2.588 *** | 0.223 | <.001 | 13.296 | (8.585–20.594) |
| |||||
Estimates of Model Fit | |||||
QIC | 4380.10 | ||||
QICu | 4367.54 | ||||
Sample Size | 4,054 |
Significance:
.10;
.05;
.01
Proportion of patient’s census tract population with high school education or greater
-SEER regions were examined but are not reported.